Patients allocated to group B who achieved RVR continued on RBV ( 800mg/day ) for a further 20 weeks ( B1 ; n = 42 ) while non-RVR patients received a higher dose of RBV ( 1600 mg/day ) + epoetin ( B2 ; n = 13 ) .